KEY — KeyCorp

Wall Street is constructive on the surface — the consensus rating is Moderate Buy with a $25.38 average target and 31 buys versus 18 holds — but the price is below the 20- and 50-day moving averages and RSI is only 40.37, so the tape is not confirming the bullish story. The Q2 EPS beat and NIM/guidance improvement support the positive tilt, yet the reported GAAP operating loss in Q2 and the gap between reported and adjusted revenue keep sentiment from being exuberant.

The reported quarterly data is messy and not cleanly organic. Revenue jumped about 44% between 2024-12-31 and 2025-03-31, likely due to a reporting change, divestiture, or acquisition effect rather than pure momentum. Since then, quarterly revenue ran in the $2.7–$2.9 billion range through Q1 2026, then reported Q2 2026 revenue fell to $2.059 billion with operating income of -$59 million, even though net income stayed positive at $509 million thanks to non-operating items. So on a reported basis this is a decelerating/inflecting trend, not a clean uptrend, and the positive adjusted narrative in the research brief deserves skepticism until the GAAP operating line turns positive again.

Fair, not cheap. The stock trades at 12.7x trailing EPS of $1.895, which is modestly above its own 5-year average P/E of 11.84x. Price-to-sales of 2.27x is also above the 5-year average of 2.03x, and price-to-book of 1.19x is not distressed. The PEG ratio of 0.005 is meaningless here because trailing EPS includes recovery from prior losses. The forward P/E is about 12.0x on estimated EPS of $1.827, leaving no valuation cushion for the execution risk embedded in the reported numbers.

At $22.02, the market is pricing roughly 12x forward earnings, which is neither a deep-value entry nor a growth premium. It is a show-me pricing: investors are refusing to pay for the turnaround until reported operating income and cash flow actually confirm the adjusted EPS story. If NIM crosses 3%, loan growth holds up, and the new $3 billion buyback shrinks share count, forward earnings could rise toward $1.95–$2.00 and support a $24–$25 stock. But if the negative reported operating income in Q2 2026 is a warning rather than a one-off, the current price has little earnings cushion and could drift toward the low-$20s or lower.

As of 2026-08-27, RSI stood at 40.37 — weak but not oversold. Price was 2.36% below the 20-day SMA and 3.63% below the 50-day SMA, but 3.4% above the 200-day SMA. That is a range-bound, slightly soft technical picture: no momentum confirmation, no panic selling. A more attractive entry would be near the low-$20s or lower, or a decisive break back above the 50-day SMA with volume.

• Higher-for-longer interest rates are a mixed tape for regional banks, but KeyCorp's asset/liability repositioning is now helping NIM expand — Q2 2026 NIM reached 2.89% and management expects >3.0% by year-end.
• Funding costs and deposit competition remain the swing factor: if deposit repricing outpaces loan yields, the margin recovery could stall.
• Commercial real estate and commercial loan credit quality is still under scrutiny; net charge-offs are low but non-performers have had idiosyncratic bumps.
• A firmer investment banking/M&A pipeline is a tailwind, especially with the Clearwater UK acquisition adding international advisory exposure.
• Capital return is becoming a bigger part of the story via the new $3 billion buyback authorization, which can mechanically lift EPS but also signals limited high-ROIC organic deployment.

• Q3 2026 earnings due mid-October 2026: investors will look for GAAP operating income to turn positive and NIM to move closer to 3.0%.
• Execution of the $3 billion buyback and continued share-count reduction.
• Clearwater integration/cross-sell updates and any signs of investment banking revenue momentum.
• Further evidence that credit costs stay contained and net charge-offs remain low.

• Reported Q2 2026 operating income was -$59 million even though adjusted EPS beat, highlighting a real gap between core operating performance and the headline number.
• The score's own note flags a possible accounting/reporting distortion around 2024-2025; if the recent revenue pattern is not clean, both trailing and forward estimates could be unreliable.
• Macro risks: if the Fed cuts sooner than expected, NIM expansion could be cut short; if rates stay high, CRE stress and funding costs could bite.
• The $3 billion buyback is aggressive relative to current market cap (~13% of shares) and could mask a lack of more productive capital deployment, while M&A integration always carries execution risk.

KeyCorp has real positive catalysts — margin expansion, capital return, and better investment banking momentum — but the reported fundamentals right now are weak, and the stock is not cheap enough to absorb disappointment. This is a wait-and-see situation: either buy at a lower price near the $20–21 support zone, or wait for a quarter where GAAP operating income and cash flow convincingly confirm the adjusted recovery story.

Calculated by applying a justified forward P/E of 12.5x to next-fiscal-year estimated EPS of $1.827 — 12.5x is slightly above KeyCorp's 5-year average P/E of 11.84x but below the current trailing multiple of 12.7x, reflecting the improving NIM/buyback story while still penalizing the weak reported operating profitability and uncertain data quality.